drugset
drugset / Trial / NCT04521881

Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults

NCT04521881 ↗

Phase 3 Recruiting 5000 enrolled London School of Hygiene and Tropical Medicine
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Tranexamic acid (TXA) reduces head injury deaths. The CRASH-4 trial aims to assess the effects of early intramuscular TXA on intracranial haemorrhage, disability, death, and dementia in older adults with symptomatic mild head injury

Timeline

Start
2021-04-18
Primary completion
2026-12-31
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tranexamic Acid Small molecule 500 mg Intramuscular

Indications

traumatic brain injury